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ABSTRACT  37 
Objective. Rheumatoid cachexia (muscle wasting) in rheumatoid arthritis (RA) patients contributes to 38 
substantial reductions in strength and impaired physical function. The objective of this randomised control 39 
trial was to investigate the effectiveness of oral creatine (Cr) supplementation in increasing lean mass and 40 
improving strength and physical function in RA patients. 41 
Method. In a double-blind design, 40 RA patients, were randomised to either 12 weeks supplementation of 42 
Cr or placebo. Body composition (dual energy x-ray absorptiometry, DXA, and bioelectrical impedance 43 
spectroscopy, BIS), strength and objectively-assessed physical function were measured at: baseline, day 6, 44 
week 12 and week 24. Data analysis was performed by ANCOVA.  45 
Results. Creatine supplementation increased appendicular lean mass (ALM; a surrogate measure of muscle 46 
mass) by 0.52 (± 0.13) kg (P = 0.004 versus placebo), and total LM by 0.60 (± 0.37) kg (P = 0.158). The 47 
change in LM concurred with the gain in intracellular water (0.64 ± 0.22 L, P = 0.035) measured by BIS. 48 
Despite increasing ALM, Cr supplementation, relative to placebo, failed to improve isometric knee extensor 49 
(P = 0.408), handgrip strength (P = 0.833), or objectively-assessed physical function (P’s = 0.335 – 0.764). 50 
Conclusion. In patients with RA, creatine supplementation increased muscle mass, but not strength or 51 
objective physical function. No treatment-related adverse effects were reported suggesting that Cr 52 
supplementation may offer a safe and acceptable adjunct treatment for attenuating muscle loss; this 53 
treatment may be beneficial for patients suffering from severe rheumatoid cachexia.  54 
 55 
ABSTRACT WORD COUNT: 240/250 56 
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SIGNIFICANCE AND INNOVATIONS: 58 
 Oral creatine supplementation improves lean mass, but not strength and objectively-assessed physical 59 
function, in patients with rheumatoid arthritis (RA). 60 
 61 
 Oral creatine supplementation offers a safe, low-cost and acceptable means of increasing muscle mass 62 
in RA patients. 63 
  64 
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INTRODUCTION 65 
Substantial loss of lean mass (LM), termed ‘rheumatoid cachexia’ (1), is common in patients with 66 
rheumatoid arthritis (RA) (2). This loss is a major contributor to the decreased strength (3) and impaired 67 
physical function (2, 4-6) which characterise this disease. Unfortunately, current drug treatments for RA, 68 
including use of biologics and the ‘treat-to-target (T2T)’ strategy (7), do not reverse this LM loss, nor fully 69 
restore physical function (8-10). Whilst high-intensity exercise (specifically, progressive resistance training 70 
(PRT)) has been shown to be highly effective in restoring both LM and function in RA patients (5, 11), the 71 
lack of uptake and adherence to sufficiently intense training (12) means this form of therapy is not widely 72 
adopted. Anabolic nutritional supplementation offers a potential adjunct treatment intervention for 73 
increasing LM, and thereby improving physical function, that could be widely accepted. Indeed, our group 74 
(13) has previously demonstrated that 12 weeks of daily oral protein supplementation improved LM and 75 
some measures of strength and function in RA patients.  76 
 77 
Creatine (Cr), a combination of essential amino acids, is a popular dietary supplement generally shown to 78 
have greater benefits on both LM and physical function than generic protein supplementation (14, 15). Oral 79 
Cr supplementation is able to enhance ATP re-synthesis by increasing initial stores of phosphocreatine 80 
(PCr) in the muscle, and thereby aid recovery during and after physical activity (16). Creatine 81 
supplementation also increases LM (14). Following Cr uptake, extracellular water (ECW) is absorbed by 82 
muscle via osmosis in order to restore intramuscular protein levels (16-18), and the resulting increase in 83 
mechanical stress caused by the expansion in intracellular water (ICW) has been proposed to act as an 84 
anabolic signal for protein synthesis (18-20). 85 
 86 
Creatine has been shown to be effective in increasing LM and improving performance in a range of athletic 87 
(e.g., (21, 22) and clinical populations (23), including muscular dystrophy patients and the elderly who, 88 
like RA patients, present with reduced muscle mass and impaired physical function (for a review see 24). 89 
However, to date only one study (25) has investigated the efficacy of Cr supplementation in RA patients. 90 
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In this short uncontrolled trial, twelve patients underwent 3 weeks of supplementation, and although 91 
strength increased, no changes in subjective function or muscle Cr levels were found, and body composition 92 
changes were not investigated. Thus, the findings of the trial are inconclusive, although they do provide 93 
some indication that Cr supplementation may be efficacious in RA patients.  94 
 95 
The current study aimed to investigate the effects of 12 weeks of oral Cr supplementation on body 96 
composition, strength and objectively-assessed physical function in patients with RA. We hypothesised that 97 
Cr supplementation would (1) increase LM and (2) improve strength and objective physical function.  98 
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PATIENTS AND METHODS  99 
A 24-week, double-blind, randomised, placebo-controlled trial was conducted between April 2013 and 100 
August 2014 at the School of Sport, Health and Exercise Science, Bangor University, UK. Patients with 101 
stable RA (i.e. no change in medication in the preceding 3 months) were recruited from outpatient clinics 102 
at the Peter Maddison Rheumatology Centre, Llandudno, North Wales, UK. For inclusion, participants had 103 
to: (a) fulfil the American College of Rheumatology/European League Against Rheumatism 2010 revised 104 
criteria for the diagnosis of RA (26); (b) be aged ≥18 years; (c) not be cognitively impaired; (d) be free of 105 
other cachectic conditions preventing safe participation; (e) have an estimated glomerular filtration rate 106 
(eGFR) ≥60 mL/min/1.73m2 (i.e. no evidence of renal impairment); (f) not be taking anabolic supplements; 107 
(g) not be currently participating in regular, high-intensity exercise; and (h) not be pregnant. Research was 108 
carried out in compliance with the Helsinki Declaration, approved by the North Wales Research Ethics 109 
Committee–West and registered as ISRCTN37558313. 110 
 111 
Supplementation and randomisation protocol 112 
Participants were randomised to receive a drink containing either supplementary Cr (treatment) or placebo 113 
for 12 weeks. Randomisation was independently performed using a secure online system by the North 114 
Wales Organisation for Randomised Trials in Health (NWORTH), a registered clinical trials unit. Groups 115 
were matched for sex and age (stratification variables: 18-44, 45-59, 60+ years), and both experimenter 116 
(TJW) and participants were blinded to supplement assignment until trial completion. 117 
 118 
In accordance with manufacturer recommendations, and previous strategies (e.g. 25, 27), the Cr group 119 
received 20g of Cr monohydrate (myprotein.co.uk, UK) (4x5g/day) for the initial 5-days (‘loading dose’) 120 
followed by 3g/day for the remainder of the 12 week period (‘maintenance dose’). The Cr was mixed with 121 
a mango-flavoured drink powder (Foster Clarks Ltd, EU) to improve taste. The placebo group received 122 
only the flavoured drink powder. Both groups received their supplements in individually portioned packets, 123 
which they were instructed to dilute with water to produce a fruit-flavoured drink. The appearance of the 124 
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treatment and placebo packets, and the flavouring and colouring of the drink mixtures, were 125 
indistinguishable. Adherence was monitored through return of the empty packets. Participants were asked 126 
to maintain routine physical activity and dietary habits and notify the investigators of any substantial 127 
lifestyle changes. 128 
 129 
Assessments and outcome measures 130 
Participants were assessed at baseline (pre-supplementation), day 6 (post-loading phase), week 12 131 
(immediately after cessation of supplementation), and week 24 (follow-up, 12 weeks after cessation of 132 
supplementation). For each assessment, participants presented fasted, and having refrained from strenuous 133 
exercise, caffeine and alcohol in the preceding 24 hours. Demographic and clinical information was 134 
collected by interview and review of medical records.  135 
 136 
Anthropometric measures. Body mass (BM) was measured to the nearest 0.1 kg using digital floor scales 137 
(SECA 635, UK), and height to the nearest 0.5 cm using a wall-mounted stadiometer (Body Care, UK), in 138 
accordance with standard procedures (28). 139 
 140 
Body composition. Total and regional lean, fat, and bone masses were estimated using a whole body fan-141 
beam dual energy X-ray absorptiometry (DXA) scanner (Hologic, QDR Discovery 45615, software V12.4). 142 
Appendicular LM (ALM; i.e. the summed LM of the arms and legs) was used as a surrogate measure of 143 
total body muscle mass (5, 11, 13). Total body water (TBW), ICW and ECW were estimated using 144 
bioelectrical impedance spectroscopy (BIS; Hydra 4200, Xitron Technologies, USA). The impedance 145 
measurements were taken in accordance with the manufacturer’s wrist-to-ankle protocol.  146 
 147 
Strength and objective physical function 148 
Strength. Isometric maximal voluntary knee extensor strength (IKES) was measured using an isokinetic 149 
dynamometer (Humac Cybex Norm 2004, Computer Sports Medicine Inc, USA). Participants were seated 150 
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on the dynamometer chair, the hip and knee flexed to 90 and the dynamometer arm attached to the lower 151 
leg just above the malleolus, with the axis of rotation aligned with the lateral condyle of the femur. After a 152 
submaximal warm-up, participants were asked to exert maximum force (Newtons (N)) for ~3 seconds. Both 153 
the right and left leg were tested three times each, with a minutes rest between trials, and the average of the 154 
best score for each leg was used for statistical analysis. Maximal voluntary handgrip strength (HGS) was 155 
measured using a Grip-A dynamometer (Takei Kiki Kogyo, Japan). For this test, participants squeezed the 156 
dynamometer maximally whilst simultaneously adducting the arm. After a practice trial, each hand was 157 
tested three times, with a minutes rest between trials, with the overall best score (N), from either hand, 158 
recorded. 159 
 160 
Physical function. Three objective physical function tests, specifically developed for assessing the capacity 161 
of older adults to perform activities of daily living (29) were performed: i) the ‘sit-to-stand in 30 second’ 162 
test (STS-30), which measures lower-body strength and balance, involves participants rising from a seated 163 
position on a fixed straight-back chair (seat height 43.2 cm / 17 inches) as many times as possible in 30 164 
seconds while keeping their arms folded across their chest. The number of full repetitions completed was 165 
recorded; ii) the ‘8-foot up and go test’ (8’UG) which assesses agility, speed and dynamic balance, requires 166 
participants to rise from the same seated position as for the STS-30 and walk forward around a cone 8 feet 167 
(2.44 m) away and return to a seated position as quickly as possible. For this test, the best time (out of two 168 
trials) was recorded; and iii) the ’50-foot walk test’ (50’W) records the time taken in seconds to walk 50’ 169 
in a straight line as quickly as possible. For all tests, participants had one practice before performing the 170 
test maximally. All of these tests are routinely administered by our group (5, 7, 11-13, 30). 171 
 172 
Aerobic capacity. The submaximal ‘Siconolfi’ step test (31) was used to estimate aerobic capacity 173 
(VO2max). Whilst wearing a heart rate monitor (Polar Electro, UK) participants stepped up and down a 10 174 
inch step for 3 x 3 minute stages or until the target heart rate (65% of predicted maximum heart rate (220–175 
age)) was achieved. Step rate, which was maintained using a digital metronome (Metronome 3.0, ONYX), 176 
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was increased at every stage i.e. stage 1: 17 steps per minute (SPM), and if required, stage 2: 26 SPM and 177 
stage 3: 34 SPM. A predicted VO2max was calculated using developed equations (31). 178 
 179 
Clinical measures. Disease activity was assessed by the Disease Activity Score in 28 joints (DAS28), and 180 
systemic inflammation by C-reactive protein (CRP). Physical disability was subjectively assessed by the 181 
Multidimensional Health Assessment Questionnaire (MDHAQ) (32) To determine subject eligibility, and 182 
examine the effect on renal function, estimated glomerular filtration rate (eGFR) was monitored at baseline 183 
and then periodically over the course of the treatment period from patients’ regular blood screenings. 184 
 185 
Statistical analysis 186 
An a-priori power calculation indicated that a minimum sample of 12 per group was required (based on a 187 
significant increase in muscle strength index (MSI) following Cr supplementation in RA patients: mean Δ 188 
= 7.4 MSI units (%), standard deviation (SD) Δ = 9.8, effect size (ES) = 0.8, P = 0.05, power = 0.80 (25)). 189 
To allow for dropouts we aimed to recruit 20 patients per group. The primary outcome measure was ALM 190 
(i.e. muscle mass). Differences between groups for outcome variables at each assessment point were tested 191 
by analysis of variance (ANCOVA), with baseline values controlled as a co-variant. Confidence intervals 192 
(CI) (95%) and ES (eta squared, η2: small ≥ 0.01; medium ≥ 0.08; large ≥ 0.26; very large ≥ 0.50) were 193 
calculated, and Pearson product–moment correlation assessed relationships (r) of interest. Chi-squared tests 194 
were used for comparison of dichotomous variables. Unless otherwise stated, data is presented as mean (± 195 
standard error (SE)), with significance set at P < 0.05 and a trend as P < 0.10. 196 
 197 
Where appropriate, the expectation-maximization algorithm (EM) was used to impute missing DXA (8% 198 
of data points missing; 12/140), IKES (6%; 9/140), HGS (5%; 7/140), STS-30 (5%; 7/140), 8’UG (5%; 199 
7/140), 50’W (7%; 10/140)) values and restore sample size. Expectation-maximization is based on two 200 
iterating (50 iterations were used) steps – expectation and maximization – which generate means and 201 
variances for missing data based on known values for that variable. Little's MCAR test and Separate 202 
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Variance t-tests confirmed the suitability of using EM on our dataset. Statistical guidance was provided by 203 
NWORTH, and data was analysed using SPSS 20 software.  204 
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RESULTS  205 
 206 
Baseline demographics 207 
Forty patients were randomised and commenced treatment with either Cr (n = 18) or placebo (n = 22). The 208 
flow of patients through the study is shown in Figure 1. For patients who completed the trial (Cr: n = 15; 209 
placebo: n = 20), there were no statistically significant differences in demographic, disease, treatment, body 210 
composition, strength or objective physical function variables between the groups at baseline, although the 211 
placebo group were somewhat larger (BM, LM and FM) and consequently tended to be stronger (Table 1).  212 
 213 
Treatment safety and compliance 214 
Five patients withdrew from the trial. In the Cr group, one female (64 years) withdrew complaining of 215 
lethargy and aching muscles [this was not considered treatment related, and was attributed to fatigue 216 
following function testing due to poor physical fitness, obesity, being a smoker, and having moderate 217 
disease activity], and a female and a male were both withdrawn due to disease flare. In the placebo group, 218 
one male suffered from a reoccurrence of angina (prior history), and one female was withdrawn due to 219 
disease flare. 220 
 221 
Over the 12 week treatment period, no changes in DAS28 were observed in either group (Cr = -0.1 ± 0.2; 222 
placebo = -0.1 ± 0.2; between-group difference: 0.0 (95% CI: -0.6-0.6), P = 0.990, η2 = 0.00)). No 223 
treatment-related adverse side effects were reported in the Cr group, and all patients’ eGFR remained ≥ 60 224 
mL/min/1.73m2. The supplementary drinks were well received, with no differences in compliance (P = 225 
0.896; mean consumption of 99% of provided supplement consumed, range 87-100%; and mean 99%, 226 
range 80-100%, for Cr and placebo, respectively). All participants declared no substantial changes in diet, 227 
medication and lifestyle during the study.  228 
 229 
 230 
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Treatment effectiveness  231 
Body composition. The effects of Cr supplementation on body composition are presented in Table 2. 232 
Twelve weeks of Cr supplementation resulted in a significant increase in ALM of 0.52 (± 0.13) kg in the 233 
Cr group, with no change in the placebo group (0.05 (± 0.13) kg; between-group P = 0.004, η2 = 0.23 234 
(medium)). Similarly, total LM increased by 0.60 (± 0.37) kg) following Cr supplementation, with no 235 
change in the placebo group over the same period (-0.06 (± 0.29) kg), albeit the between-group change was 236 
not significant (P = 0.158, η2 = 0.06 (small)). The increase in LM accounted for most of the 1.10 (± 0.58) 237 
kg BM gain observed in these patients from baseline to week 12 (P = 0.195, η2 = 0.06 (small)). In the Cr 238 
group there was an increase in ICW from baseline to week 12 (0.64 ± 0.22 L, P = 0.035, η2 = 0.13 (medium)) 239 
and this change was weakly correlated with the ALM increase (r = 0.481, P = 0.082). 240 
 241 
At week 24, the increases from baseline values for ALM (P = 0.293, η2 = 0.03 (small)) and total LM (P = 242 
0.977, η2 = 0.00) were comparable for both groups. This indicates a regression back to baseline for ALM 243 
and total LM in the Cr group following supplementation cessation and further supports a treatment effect. 244 
From weeks 12 to 24, the decline in ALM in the Cr group corresponded with reductions in water 245 
compartments (TBW (r = 0.801, P = 0.001) and, more pertinently, ICW (r = 0.711, P = 0.004). No changes 246 
in total FM or body fat % were observed at any time point, and, similarly, no significant changes in any 247 
aspect of body composition were detected at day 6, for either group. 248 
 249 
Strength and physical function. The effects of Cr supplementation on strength and objective physical 250 
function measures are displayed in Table 3. There was no change in IKES over the 12 week treatment 251 
period with the increase over time between the groups comparable (P = 0.408, η2 = 0.02 (small)). Following 252 
12 weeks cessation of Cr supplementation, IKES was seemingly increased in the Cr group, as evidenced 253 
by a 34.3 (± 13.7) N increase from baseline to week 24 (P = 0.075, η2 = 0.10 (medium)) relative to the 254 
placebo group. However, this trend was the result of one participant who improved by 143.0 N from 255 
baseline to week 24. Removing this individual resulted in the loss of this trend (adjusted means, baseline 256 
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to week 24 change: Cr = 24.8 (± 13.6) N, placebo = 1.9 (± 11.3) N, between-group difference: 22.9 (95% 257 
CI: -14.0-59.7) P = .215, η2 = 0.05 (small)). Similarly, there were no differences between the two groups 258 
in changes in HGS from baseline to week 12 (P = 0.833, η2 = 0.00), or to week 24 (P = .969, η2 = 0.00).  259 
 260 
Consistent with the lack of effect on strength measures, there were no meaningful changes in any of the 261 
objective physical function measures, as both groups improved their STS-30, 8’UG and 50’W test 262 
performances comparably (between-group P’s = 0.764, 0.555 and 0.335, respectively, for baseline to week 263 
12 between-group changes). Creatine supplementation also had no effect on estimated VO2max (L/min) 264 
(between-group P = 0.762, η2 = 0.00), or self-reported physical disability (MDHAQ) (Cr = -0.1 ± 0.1, 265 
placebo = -0.1 ± 0.1; between-group difference, 0.0 (95% CI: -0.3-0.4), P = 0.836, η2 = 0.06 (small)) over 266 
the 12 week supplementation period. 267 
 268 
269 
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DISCUSSION  270 
Our results indicate that Cr supplementation improves body composition, specifically muscle mass, but not 271 
strength or objective physical function in patients with RA. In the current study, ALM, by 0.52 kg, and total 272 
LM, by 0.60 kg, increased following 12 weeks Cr supplementation. Whilst there was a small and non-273 
significant increase in FM as a consequence of Cr supplementation (0.41 ± 0.45 kg), the greater gain in 274 
ALM meant that proportional muscle mass (ALM/BM%) was not diminished (27.4% to 27.7%, 275 
respectively) from baseline to week 12. The addition of LM observed in the Cr group cannot be attributed 276 
to increased calorie intake. Twelve weeks of Cr supplementation resulted in an additional calorie intake of 277 
approximately 1348kcal (based on ~4kcal/g protein). Given that 1 kg FM ≈ 7700 kcal, this overnutrition 278 
would equate to a FM gain of ~0.18kg. The difference observed in FM gain between the Cr and placebo 279 
groups was 0.23g, therefore whilst the additional calories account for the majority of the difference in FM 280 
gain, they do not account for the difference in LM (a 0.60kg increase in the Cr group). 281 
 282 
The magnitude of LM increase we observed is comparable to that seen previously in older men (33), older 283 
women (34, 35), and patients with muscle dystrophy (36) following Cr supplementation. The body 284 
composition changes are also similar to those we previously observed following 12 weeks of protein 285 
supplementation in RA patients (i.e. increases of 0.40 kg in ALM and 0.73 kg in total LM, whilst FM 286 
remained unchanged (13)). These results, together with the response to PRT (5, 11), and the finding that 287 
muscle quality (i.e. maximal force exerted per unit muscle) is not impaired in RA patients (30), further 288 
emphasise that RA patients are not, as previously believed (37), resistant to muscle anabolic stimuli. 289 
 290 
The changes in ALM following 12 weeks Cr supplementation were reflected in changes in body water, 291 
specifically a significant 1.08 L increase in TBW due to expansion of both ICW (0.64 L), and ECW (0.44 292 
L) during this period. Similar changes in body water were observed in younger adults following Cr 293 
supplementation (17, 18, 20). The mechanisms by which Cr supplementation increases TBW and shifts 294 
fluid into the intracellular space are unclear (17). However, it is has been suggested that as skeletal muscle 295 
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cell Cr and PCr concentrations rise, ECW is drawn into the cell by osmosis to maintain intracellular protein 296 
concentration (17, 18, 38). The uptake of Cr into the muscle following supplementation (16), and 297 
subsequent increases in mechanical stress caused by the rise in ICW have been postulated to stimulate 298 
protein synthesis (19), although it is unclear if Cr augments muscle protein by this mechanism (18). In our 299 
trial, at week 24 (i.e. 12 weeks after Cr supplementation ceased), ICW returned towards its baseline level 300 
and, over the same ‘washout’ period, 0.12 kg ALM and 0.38 kg total LM were lost. These reversions to, or 301 
toward, baseline over the 12 week withdrawal period, provide further evidence that the changes seen at 302 
week 12 are due to Cr supplementation. Interestingly, at week 24, despite the losses due to withdrawal of 303 
Cr, ALM and total LM were still 0.40 kg and 0.21 kg, respectively, above baseline values, suggesting some 304 
longer term retention of body composition changes following Cr supplementation.  305 
 306 
The lack of a Cr-induced improvement in either strength or function that we observed in this study contrasts 307 
with the 14% gain in composite strength reported by Willer et al (25) following short-term Cr 308 
supplementation in RA patients. Similarly, improvements in both strength (IKES and HGS) and objective 309 
physical function measures, such as the 5-repetition STS and 6m tandem walk test, following Cr 310 
supplementation have been observed in older adults (24, 33-35, 39, 40), as well as other clinical groups 311 
such as patients with fibromyalgia (41) and muscle dystophy (36). However, the effects of Cr 312 
supplementation on measures of strength and function are equivocal. Creatine supplementation had no 313 
effect on HGS, IKES, timed 30ft walk (30’W) and a timed four step climb test (SCT) in osteoarthritic 314 
patients following surgery (44), whilst in patients with muscular dystrophy, supplementation with Cr failed 315 
to improve HGS or IKES (42-44), or function: SCT, 30’W and time taken to stand from supine (36, 44, 316 
45). Furthermore, despite eliciting an increase in LM, no improvement in ankle dorsiflexion strength was 317 
reported by Sakkas et al (46) in 20 HIV–positive men following 2 weeks of Cr supplementation. 318 
Additionally, several studies in older adults (24, 47-49) found no benefit of Cr supplementation on either 319 
strength or function.  320 
 321 
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Since both groups in our trial had comparable improvements in the function tests, it suggests that, despite 322 
prior practice, performance was enhanced by a learning effect. In keeping with the literature, Cr 323 
supplementation in our investigation had no effect on aerobic capacity (21, 22, 41). 324 
  325 
Responsiveness to Cr supplementation is reported to vary with only ~70-75% of individuals, irrespective 326 
of age, deemed to be ‘responders’ (16, 50). The main determinant of ‘responsiveness’ is thought to be initial 327 
muscle Cr concentrations, as when this is high (~150 mmol·kg-1dw) supplementation does not appear to 328 
augment muscle Cr.  (50). Consistent with this estimation, strength increases were noted in 67% of RA 329 
patients in the Willer et al study, and in our study, 80% of participants ‘responded’, when ‘response’ is 330 
defined by increased ALM (≥ 0.24 kg).  331 
 332 
In the current study, oral Cr supplementation was well tolerated, with high compliance and no adverse side 333 
effects. Additionally, supplementation had no effects on RA disease activity or renal function (eGFR), thus 334 
providing further evidence that supplementing with Cr is safe (18, 25, 33). Although the lack of effects on 335 
strength and physical function are disappointing, the increase in LM we demonstrated suggests that Cr 336 
supplementation may be beneficial in patients with severe rheumatoid cachexia, since a marked loss of LM 337 
both impairs the body’s ability to fight infection due to limited expendable protein reserve for immune cell 338 
production, and increases the risk of mortality (2). The lack of efficacy demonstrated on physical function 339 
in this study further emphasises that sustained PRT (5, 11, 12) should be performed by RA patients wishing 340 
to substantially increase LM, and, subsequently, restore their strength and physical functioning.  341 
 342 
CONCLUSION  343 
In patients with RA, 12 weeks of oral Cr supplementation had beneficial effects on muscle mass, but not 344 
on strength or objectively-assessed physical function. Given compliance to Cr was high, and no adverse 345 
treatment related effects were observed, Cr may offer an acceptable, safe, low-cost, and reasonably effective 346 
means for RA patients with severe rheumatoid cachexia to help restore muscle mass. However, for patients 347 
Oral creatine supplementation in RA 
18 
 
wishing to improve their muscle mass and their strength and physical function, PRT should be performed 348 
as an adjunct therapy option. 349 
  350 
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Table 1. Baseline demographics of rheumatoid arthritis patients who underwent 12 weeks of oral 526 
creatine or placebo supplementation 527 
 Creatine (n = 15) Placebo (n = 20) P 
Age (years) 63.0 (± 10.0) 57.2 (± 10.4) 0.104 
Sex (female) (%) 10 (67) 14 (70) 0.833 
Disease duration (months) 112.4 (± 82.8) 141.4 (± 160.1) 0.493 
Rheumatoid factor +, n (%) 8 (53) 13 (65) 0.376 
Height (cm) 165.1 (± 7.9) 166.1 (± 9.1) 0.734 
BM (kg) 67.31 (± 10.29) 76.73 (± 18.99) 0.092# 
BMI (kg/m2) 24.7 (± 3.6) 27.8 (± 6.6) 0.113 
ALM (kg) 18.4 (± 4.2) 20.6 (± 5.7) 0.227 
Total LM (kg) 45.9 (± 8.5) 50.1 (± 12.4) 0.274 
Total FM (kg) 19.8 (± 7.2) 24.9 (± 10.5) 0.113 
DAS28 2.8 (± 0.8) 2.6 (± 0.9) 0.608 
Medications, n (%)    
NSAIDS  4 (27) 10 (50) 0.163 
Methotrexate 9 (60) 12 (60) 1.000 
Other DMARDS 6 (40) 7 (35) 0.889 
Biologics  1 (7) 4 (20) 0.617 
Current corticosteroids a 2 (13) 2 (10) 0.759 
Strength and physical function measures 
IKES (N) 348.3 (± 156.3) 417.3 (± 126.9) 0.159 
HGS (N) 236.6 (± 92.8) 237.9 (± 99.8) 0.969 
STS-30 (reps) 11.7 (± 4.0) 13.2 (± 2.9) 0.206 
8’UG (secs) 8.2 (± 3.3) 6.6 (± 1.7) 0.119 
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50’W (secs) 11.0 (± 4.0) 9.8 (± 2.2) 0.300 
VO2max (L/min) 1.8 (± 0.4) 1.7 (± 0.5) 0.918 
MDHAQ 0.5 (± 0.5) 0.5 (± 0.4) 0.917 
BM = body mass; BMI = body mass index; ALM = appendicular lean mass; FM = fat mass; DAS28 = 528 
disease activity score in 28 joints; NSAIDS = non-steroidal anti-inflammatory drugs; DMARDS = disease 529 
modifying anti-rheumatic drugs; IKES = isometric knee extensor strength; HGS = handgrip strength; STS-530 
30 = sit-to- stand in 30 second test; 8’UG = 8-foot up and go; 50’W = 50-foot walk; VO2max = estimated 531 
V02max from Siconolfi step test; MDHAQ = health assessment questionnaire. 
a = current corticosteroid 532 
use, range 2.5–5.0 mg. Unless stated, data presented as mean (± SD). * = P < 0.05; # = P < 0.10. 533 
  534 
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Table 2. Changes in body composition in rheumatoid arthritis patients following 12 weeks oral 535 
creatine supplementation 536 
  Creatine (n = 15) Placebo (n = 20) Differences between-group for ∆ 
  Mean (± SE) Mean (± SE) Mean (CI) P η2 
ALM (kg) Δ B–12 0.52 (± 0.13) 0.01 (± 0.11) 0.52 (0.18-0.86) 0.004* 0.23 
 Δ B–24 0.40 (± 0.18) 0.15 (± 0.15) 0.25 (-0.23-0.73) 0.293 0.03 
Total LM (kg) Δ B–12 0.60 (± 0.37) -0.06 (± 0.29) 0.65 (-0.27-1.57) 0.158 0.06 
 Δ B–24 0.21 (± 0.37) 0.19 (± 0.32) 0.01 (-0.99-1.01) 0.977 0.00 
BM (kg) Δ B–12 1.10 (± 0.58) 0.11 (± 0.46) 0.99 (-0.54-2.52) 0.195 0.06 
 Δ B–24 0.61 (± 0.70) 0.92 (± 0.55) -0.31 (-2.15-1.53) 0.736 0.00 
Total FM (kg) Δ B–12 0.41 (± 0.45) 0.18 (± 0.37) 0.23 (-0.94-1.40) 0.693 0.01 
 Δ B–24 0.65 (± 0.52) 0.48 (± 0.45) 0.17 (-1.26-1.60) 0.810 0.00 
Body fat (%) Δ B–12 0.1 (± 0.4) 0.5 (± 0.3) -0.3 (-1.4-0.8) 0.595 0.01 
 Δ B–24 0.3 (± 0.5) 0.6 (± 0.4) -0.3 (-1.6-1.0) 0.608 0.01 
TBW (L) Δ B–12 1.08 (± 0.27) -0.01 (± 0.23) 1.07 (0.34-1.8) 0.005* 0.22 
 Δ B–24 0.42 (± 0.31) -0.11 (± 0.27) 0.53 (-0.32-1.37) 0.213 0.05 
ICW (L) Δ B–12 0.64 (± 0.22) -0.01 (± 0.19) 0.65 (-0.05-1.24) 0.035* 0.13 
 Δ B–24 0.12 (± 0.24) -0.10 (± 0.20) 0.22 (-0.41-0.85) 0.481 0.02 
ECW (L) Δ B–12 0.44 (± 0.11) 0.0 (± 0.09) 0.44 (-0.15-0.73) 0.004* 0.23 
 Δ B–24 0.36 (± 0.12) 0.03 (± 0.11) 0.36 (0.03-0.68) 0.035* 0.13 
ALM = appendicular lean mass; BM = body mass (scales); FM = fat mass; TBW = total body water; ICW 537 
= intracellular water; ECW = extracellular water. Changes (Δ) between time points (B = baseline, 12 = 538 
week 12 (immediately post-supplementation); 24 = week 24 (12 weeks post-supplementation)) are 539 
presented as the adjusted mean (± SE) from ANCOVA. The between-group difference for each Δ is 540 
displayed with 95% confidence interval (CI) along and effect size, eta squared (η2): small = 0.01; medium 541 
= 0.08; large = 0.26; very large = 0.50. * = P < 0.05; # = P < 0.10.  542 
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Table 3. Changes in strength and objective physical function measures in rheumatoid arthritis 543 
patients following 12 weeks oral creatine supplementation 544 
  Creatine (n = 15) Placebo (n = 20) Differences between-group for ∆ 
  Mean (± SE) Mean (± SE) Mean (CI) P  η2 
IKES (N) Δ B–12 25.8 (± 11.6) 12.8 (± 10.0) 13.0 (-18.6-44.6) 0.408 0.02 
 Δ B–24 34.3 (± 13.7) 0.7 (± 11.8) 33.6 (-3.6-70.9) 0.075# 0.10 
HGS (N) Δ B–12 11.0 (± 6.8) 9.1 (± 5.9) 1.9 (-16.3-20.1) 0.833 0.00 
 Δ B–24 9.5 (± 6.0)  9.2 (± 5.2) 0.3 (-15.9-16.6) 0.969 0.00 
STS-30 (reps) Δ B–12 2.0 (± 0.7) 1.8 (± 0.5) 0.2 (-1.6-1.9) 0.764 0.02 
 Δ B–24 2.1 (± 0.7) 2.3 (± 0.6) -0.2 (-1.9-1.4) 0.856 0.01 
8’UG (secs) Δ B–12 -0.44 (± 0.24) -0.25 (± 0.21) -0.19 (-0.85-0.46) 0.555 0.01 
 Δ B–24 -0.29 (± 0.30) -0.32 (± 0.26) 0.03 (-0.80-0.86) 0.943 0.00 
50’W (secs) Δ B–12 -0.31 (± 0.23) -0.61 (± 0.20) 0.30 (-0.32-0.91) 0.335 0.03 
 Δ B–24 -0.23 (± 0.25) -0.40 (± 0.22) 0.17 (-0.50-0.85) 0.606 0.08 
VO2max (L/min) Δ B–12 0.0 (± 0.0) 0.0 (± 0.0) 0.0 (-0.1–0.1) 0.762 0.00 
 Δ B–24 0.0 (± 0.1) 0.1 (± 0.0) -0.1 (-0.2-0.1) 0.219 0.06 
IKES = isometric knee extensor strength; HGS = handgrip strength; STS-30 = sit-to- stand in 30 second 545 
test; 8’UG = 8-foot up and go; 50’W = 50-foot walk; VO2max = estimated V02max from Siconolfi step 546 
test. Changes (Δ) between time points (B = baseline, 12 = week 12 (immediately post-supplementation); 547 
24 = week 24 (12 weeks post-supplementation)) are presented as the adjusted mean (± SE) from ANCOVA. 548 
The between-group difference for each Δ is displayed with 95% confidence interval (CI) and effect size, 549 
eta squared (η2): small = 0.01; medium = 0.08; large = 0.26; very large = 0.50. * = P < 0.05; # = P < 0.10. 550 
551 
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Figure 1. Consort diagram showing recruitment and path of patients through the study 552 
 553 
Cr = Creatine supplementation group; DNC = randomised but did not commence treatment (i.e. did not 554 
attend baseline and were subsequently withdrawn); * = due to missing data, final analysis for body 555 
composition and physical function data included values using expectation-maximization imputed data; # = 556 
missed sessions (placebo) at day 6, week 12 and week 24 were not the same participant. 557 
 558 
